- Dr. Mansukh Mandaviya met with the Pharmaceutical Association of Japan to discuss collaboration in the pharmaceutical sector.
- The meeting highlighted the strength and potential of the Indian Pharma sector in manufacturing high-quality generic medicines and vaccines.
- The Pharmaceutical Association of Japan apprised Dr. Mandaviya of the initiatives and reforms undertaken by the Government of India in the pharmaceutical sector.
- The collaboration aims to foster research partnerships, knowledge sharing, and technology transfers between India and Japan to address global health challenges.
The pharmaceutical industry plays a vital role in improving global healthcare and ensuring access to essential medicines. In an effort to strengthen collaboration and foster innovation, Dr. Mansukh Mandaviya, a prominent figure in the Indian pharmaceutical sector, recently met with the Pharmaceutical Association of Japan along with the CEOs of leading pharmaceutical companies. The meeting served as a platform to discuss potential collaborations and explore avenues for mutual growth in the pharma sector.
Dr. Mansukh Mandaviya’s Meeting with the Pharmaceutical Association of Japan
The meeting between Dr. Mansukh Mandaviya and the Pharmaceutical Association of Japan was a significant step towards building strong ties between the Indian and Japanese pharmaceutical sectors. The objective was to establish a framework for collaboration, enabling the sharing of best practices, research, and technology.
Highlights of the Meeting
During the meeting, various important topics were discussed, primarily focusing on collaboration in the pharma sector. Dr. Mansukh Mandaviya highlighted the strength and potential of the Indian pharmaceutical industry, showcasing its prowess in manufacturing high-quality generic medicines, vaccines, and other essential healthcare products.
“The Pharma Association of Japan, in turn, apprised the Indian delegation of the commendable initiatives and reforms undertaken by the Government of India. These initiatives include streamlining regulatory processes, promoting ease of doing business, encouraging research and development, and ensuring quality control in the pharmaceutical sector”.
The discussion also revolved around the importance of research collaborations, knowledge sharing, and technology transfers between the two countries. Both parties acknowledged the significance of working together to address global health challenges, especially in areas such as drug discovery, clinical trials, and the development of innovative therapies.
